New combo therapy aims to shrink untreatable liver tumors

NCT ID NCT07334483

Recruiting now Disease control Sponsor: GrandPharma (China) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of radioactive beads (yttrium-90), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib) works better than standard chemoembolization for liver cancer that cannot be surgically removed. About 120 adults with non-metastatic liver cancer will be randomly assigned to different treatment groups. The main goal is to see how many patients' tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Yttrium-90 microspheres (radioactive beads), camrelizumab (immunotherapy), apatinib (targeted therapy)
What this could lead to: If successful, this could offer a more effective treatment option for people with liver cancer that cannot be removed by surgery, potentially shrinking tumors better than current standard therapy.
What could go wrong: This is a mid-stage trial with only 120 participants, so results may not apply to everyone. Combining treatments also raises the risk of side effects like liver damage or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC

Contacts and locations

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, China
Nanjing Tianyinshan Hospital
NOT_YET_RECRUITING

Nanjin, China
Zhongshan Hospital Fudan University
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.